Inclusion of Plasma Lipid Species Improves Classification of Individuals at Risk of Type 2 Diabetes
Year: 2013
Type: article
Study design: Observational Study
Abstract: BACKGROUND: A significant proportion of individuals with diabetes or impaired glucose tolerance have fasting plasma glucose less than 6.1 mmol/L and so are not identified with fasting plasma glucose measurements. In this study, we sought to evaluate the utility of plasma lipids to improve on fasting plasma glucose and other standard risk factors for the identification of type 2 diabetes or those at increased risk (impaired glucose tolerance). METHODS AND FINDINGS: Our diabetes risk classification model was trained and cross-validated on a cohort 76 individuals with undiagnosed diabetes or impaired glucose tolerance and 170 gender and body mass index matched individuals with normal glucose tolerance, all with fasting plasma glucose less than 6.1 mmol/L. The inclusion of 21 individual plasma lipid species to triglycerides and HbA1c as predictors in the diabetes risk classification model resulted in a statistically significant gain in area under the receiver operator characteristic curve of 0.049 (p<0.001) and a net reclassification improvement of 10.5% (p<0.001). The gain in area under the curve and net reclassification improvement were subsequently validated on a separate cohort of 485 subjects. CONCLUSIONS: Plasma lipid species can improve the performance of classification models based on standard lipid and non-lipid risk factors.
Source: PLoS ONE
Institution: Baker Heart and Diabetes Institute
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,382
Funders: U.S. Department of Health and Human Services, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Sanofi, Queensland Health, Pratt Foundation, Australian Government, Diabetes Australia, Kidney Health Australia, Novo Nordisk, State Government of Victoria, Menzies Institute for Medical Research, National Institutes of Health, Eli Lilly Australia, Medical Research Council, National Health and Medical Research Council, National Institute of Diabetes and Digestive and Kidney Diseases, Cilag
OpenAlex ID: W2037737079